Reuters Health Report

Click to View in Browser 09/29/2014 Walking is the superfood of fitness, experts say NEW YORK (Reuters) - Walking may never become as trendy as CrossFit, as sexy as mud runs or as ego-boosting as Ironman races but for fitness experts who stress daily movement over workouts and an active lifestyle over weekends of warrior games, walking is a super star. Seattle Genetics, Takeda's cancer drug meets main goal in trial (Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Merck immunotherapy drug shows promise in bladder cancer MADRID (Reuters) - Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year. Puma Biotechnology cancer drug shows positive mid-stage results (Reuters) - Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study. Bristol immune drug shows strong effect in melanoma study MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option. Kamada extends emphysema drug deal with Baxter through 2017 JERUSALEM (Reuters) - Israeli drugmaker Kamada said on Monday it extended an agreement with Baxter International to supply a drug to treat emphysema through 2017. Hundreds of firms join global hunt for copycat biotech drugs (Reuters) - Hundreds of companies around the world are chasing an emerging market for cheaper copies of costly biotech drugs, with more than 700 so-called biosimilars now in development or already approved, according to a major study of the sector. Tonix Pharma's pain drug fails mid-stage study (Reuters) - Tonix Pharmaceuticals Holding Corp said its lead pain drug failed the main goal of a mid-stage study, sending its shares down by nearly half in premarket trading. Roche breast cancer drug 'unprecedented' in extending lives MADRID (Reuters) - A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial and experts urged its widespread use for women with an aggressive form of the disease. Scientists grapple with ethics in rush to release Ebola vaccines LONDON (Reuters) - Normally it takes years to prove a new vaccine is both safe and effective before it can be used in the field. But with hundreds of people dying a day in the worst ever outbreak of Ebola, there is no time to wait. Related Video Genetic bacterial engineering could herald new era of biofuels Lush farms sprout amid Manila's concrete sprawl The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend